Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Adults With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Condition: Ovarian Cancer; Ovarian Neoplasm
MeSH terms: Ovarian Neoplasms
Intervention: Veliparib; Paclitaxel; Carboplatin; Placebo to Veliparib
Intervention description: Capsules for oral administration; Administered by intravenous infusion, either 80 mg/m² of body-surface area (BSA) on Days 1, 8, and 15 of each 21-day cycle (weekly dosing), or 175 mg/m² of BSA on Day 1 of each 21-day cycle (3-week dosing).; Administered by intravenous infusion at an area under the curve (AUC) of 6 mg/mL/min every 3 weeks.; Capsules for oral administration
Intervention MeSH terms: Paclitaxel; Carboplatin; Veliparib
Phase: Phase 3
Study type: Interventional
Primary purpose: Treatment
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Enrollment: 1140.0
Sex: Female
Minimum age: 18 Years
Healthy volunteers: No
Keywords: Veliparib; Carboplatin; Paclitaxel; Overall Survival; ABT-888; Randomized; Poly Adenosine Diphosphate (ADP) - Ribose Polymerase (PARP); Ovarian; BRCA; VELIA

Summary:

      The primary objective of the study was to evaluate whether progression-free survival (PFS)
      was prolonged with the addition of veliparib to standard platinum-based chemotherapy
      (carboplatin/paclitaxel [C/P]) and continued as maintenance therapy compared with
      chemotherapy alone.
    

Eligibility criteria:

        Inclusion Criteria:

          1. Histologic diagnosis of International Federation of Gynecology and Obstetrics (FIGO)
             Stage III or IV epithelial ovarian, fallopian tube, or primary peritoneal carcinoma,
             with the appropriate tissue available for histologic evaluation.

          2. High-grade serous adenocarcinoma

          3. Willing to undergo testing for gBRCA.

          4. Adequate hematologic, renal, and hepatic function.

          5. Neuropathy (sensory and motor) less than or equal to Grade 1.

          6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.

          7. Participants who undergo primary cytoreductive surgery must be entered between 1 and
             12 weeks after surgery. Participants undergoing interval surgery must have a tumor
             sample confirming the histological diagnosis prior to enrollment.

          8. Participants with measurable disease or non-measurable disease are eligible.
             Participants may or may not have cancer-related symptoms.

          9. Participant has one of the following available for pharmacodynamic analyses including
             somatic BRCA testing: Archived diagnostic formalin-fixed paraffin embedded (FFPE)
             tumor tissue; or tumor tissue biopsy collected prior to Cycle 1 Day 1.

        Exclusion Criteria:

          1. Endometrioid adenocarcinoma, carcinosarcoma, undifferentiated carcinoma, mixed
             epithelial adenocarcinoma, adenocarcinoma not otherwise specified, mucinous
             adenocarcinoma, clear cell adenocarcinoma, low-grade serous adenocarcinoma, or
             malignant Brenner's tumor.

          2. Participants with synchronous primary endometrial cancer, or a past history of
             endometrial cancer unless all of the following conditions are met: endometrial cancer
             stage not greater than IA, no vascular or lymphatic invasion, no poorly differentiated
             subtypes including serous, clear cell, or other FIGO grade 3 lesions.

          3. Participants with any evidence of other invasive malignancy being present within the
             last 3 years (with the exception of non-melanoma skin cancer). Participants are also
             excluded if their previous cancer treatment contraindicates this protocol's therapy.

          4. Received prior radiotherapy to any portion of the abdominal cavity or pelvis.

          5. Received prior chemotherapy for any abdominal or pelvic tumor.

          6. Clinically significant uncontrolled condition(s).

          7. Known history of allergic reaction to Cremophor-paclitaxel, carboplatin, Azo-Colourant
             Tartrazine (also known as FD&C Yellow 5 or E102), Azo-Colourant Orange Yellow-S (also
             known as FD&C Yellow 6 or E110) or known contraindications to any study supplied drug.

          8. History or evidence upon physical examination of central nervous system (CNS) disease,
             including primary brain tumor, any brain metastases, or history of cerebrovascular
             accident (CVA, stroke), transient ischemic attack (TIA) within 6 months of Cycle 1 Day
             1.